EBS Financial Facts
Product sales: 96.7MCost of product sales: 39.56M
See Full Income Statement
Deferred revenue, net of current portion: 4.7M
Income tax receivable, net: 11.83M
See Full Balance Sheet
Emergent BioSolutions, Inc. (EBS) Earnings
|
Expand Research on EBS
Next EPS Date | 5/1/24 | EPS Growth Rate | +73.8% |
---|---|---|---|
Average EPS % Beat Rate | -421.0% | Revenue Growth Rate | +12.3% |
Average % Move 1-Wk after EPS | -23.2% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
2/24/22 | Q421 | $4.50 | $4.27 | +$0.23 | $723.2M | $691.36M | N/A | Details | |||
2/18/21 | Q420 | $3.67 | $3.19 | +$0.48 | $583M | $563.94M | = | Details | |||
7/29/21 | Q221 | $0.33 | $1.54 | -$1.21 | $397.5M | $398.93M | = | Details | |||
7/30/20 | Q220 | $1.98 | $0.68 | +$1.30 | $394.7M | $294.73M | Details | ||||
11/5/20 | Q320 | $2.19 | $2.12 | +$0.07 | $385.2M | $437.93M | Details | ||||
2/20/20 | Q419 | $1.57 | $1.73 | -$0.16 | $360.4M | $357.41M | Details | ||||
4/29/21 | Q121 | $1.53 | $1.12 | +$0.41 | $343M | $358.47M | Details | ||||
8/8/23 | Q223 | -$1.06 | -$0.63 | -$0.43 | $337.9M | $217.03M | = | Details |